Budesonide oral suspension - Dr Falk Pharma
Latest Information Update: 30 Apr 2024
Price :
$50 *
At a glance
- Originator Dr Falk Pharma
- Class Alcohols; Anti-inflammatories; Antiallergics; Antiasthmatics; Antivirals; Dioxoles; Glucocorticoids; Pregnenediones; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Eosinophilic oesophagitis
Most Recent Events
- 19 Mar 2024 Phase II/III development is ongoing in Portugal and Spain (Dr Falk Pharma website, March 2024)
- 19 Mar 2024 Dr.Falk Pharma completes a phase II/III trial in Eosinophilic esophagitis (In children, In adolescents) in Germany, Greece, Israel, Netherlands, Portugal, Spain and United Kingdom (PO, Suspension) (EudraCT2017-003737-29)
- 22 Apr 2022 No development reported - Phase-II/III for Eosinophilic oesophagitis (In adolescents, In children) in Portugal (PO)